Unnamed: 0,title,date,stock,sentiment
1213634.0,"Benzinga's Top Upgrades, Downgrades For May 13, 2020",2020-05-13 09:58:00-04:00,TBPH,positive
1213635.0,"Cowen & Co. Initiates Coverage On Theravance Biopharma with Outperform Rating, Announces Price Target of $42",2020-05-13 07:30:00-04:00,TBPH,neutral
1213636.0,"Theravance Biopharma Q1 EPS $(1.400) Misses $(1.070) Estimate, Sales $19.900M Beat $18.130M Estimate",2020-05-06 16:28:00-04:00,TBPH,negative
1213637.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,TBPH,positive
1213638.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,TBPH,neutral
1213639.0,Theravance Biopharma Reports First Subject Dosed In Phase 1 Study Of TD-0903 In Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19,2020-04-23 06:08:00-04:00,TBPH,negative
1213640.0,Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis,2020-04-20 06:02:00-04:00,TBPH,neutral
1213641.0,Theravance Biopharma Highlights Clinical Trial Application Submitted In UK for First In Human Study Of TD-9003 For Acute Lung Injury Related To Coronavirus,2020-04-09 07:02:00-04:00,TBPH,negative
1213642.0,"HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to $32",2020-02-25 11:53:00-05:00,TBPH,neutral
1213643.0,"Piper Sandler Maintains Overweight on Theravance Biopharma, Lowers Price Target to $35",2020-02-25 09:16:00-05:00,TBPH,negative
1213644.0,Theravance Biopharma Q4 EPS $(1.17) Misses $(1.13) Estimate,2020-02-24 16:11:00-05:00,TBPH,negative
1213645.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,TBPH,neutral
1213646.0,60 Biggest Movers From Yesterday,2020-02-13 05:45:00-05:00,TBPH,neutral
1213647.0,52 Stocks Moving In Wednesday's Mid-Day Session,2020-02-12 12:13:00-05:00,TBPH,neutral
1213648.0,31 Stocks Moving in Wednesday's Pre-Market Session,2020-02-12 07:15:00-05:00,TBPH,neutral
1213649.0,94 Biggest Movers From Yesterday,2020-02-12 05:13:00-05:00,TBPH,neutral
1213650.0,Theravance Biopharma Prices 5.5M Stock Offering @$27/Share,2020-02-12 05:04:00-05:00,TBPH,neutral
1213651.0,71 Stocks Moving In Tuesday's Mid-Day Session,2020-02-11 12:21:00-05:00,TBPH,neutral
1213652.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,TBPH,positive
1213653.0,36 Stocks Moving in Tuesday's Pre-Market Session,2020-02-11 07:16:00-05:00,TBPH,neutral
1213654.0,"10 Stocks To Watch For February 11, 2020",2020-02-11 05:00:00-05:00,TBPH,neutral
1213655.0,20 Stocks Moving In Monday's After-Hours Session,2020-02-10 18:01:00-05:00,TBPH,neutral
1213656.0,Theravance Biopharma shares are trading lower after the company announced a $150 million proposed offering of ordinary shares.,2020-02-10 16:08:00-05:00,TBPH,positive
1213657.0,Theravance Biopharma Announces $150M Proposed Public Offering of Ordinary Shares,2020-02-10 16:01:00-05:00,TBPH,positive
1213658.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,TBPH,negative
1213659.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-05 10:16:00-05:00,TBPH,neutral
1213660.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,TBPH,neutral
1213661.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-04 10:18:00-05:00,TBPH,neutral
1213662.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,TBPH,negative
1213663.0,Stocks That Hit 52-Week Highs On Monday,2020-02-03 11:44:00-05:00,TBPH,neutral
1213664.0,"Theravance Biopharma And Pfizer Inc. Enter Global License Agreement For Skin-Targeted, Locally-Acting Pan-Janus Kinase Inhibitor Program; Theravance To Receive Upfront Cash Payment Of $10M And Up To $240M In Milestones",2019-12-23 08:18:00-05:00,TBPH,positive
1213665.0,"Theravance Biopharma Doses First Patient In Phase 2 Allergen Challenge Study Of TD-8236, An Investigational, Lung-Selective, Inhaled Pan-Janus Kinase Inhibitor For Inflammatory Lung Diseases",2019-12-03 07:50:00-05:00,TBPH,neutral
1213666.0,"Benzinga's Top Upgrades, Downgrades For November 6, 2019",2019-11-06 09:56:00-05:00,TBPH,positive
1213667.0,"Baird Upgrades Theravance Biopharma to Neutral, Lowers Price Target to $18",2019-11-06 06:37:00-05:00,TBPH,negative
1213668.0,"Theravance Biopharma Q3 EPS $(1.05) Beats $(1.11) Estimate, Sales $12.427M Beat $11.62M Estimate",2019-11-05 16:26:00-05:00,TBPH,neutral
1213669.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,TBPH,negative
1213670.0,"Benzinga's Top Upgrades, Downgrades For October 29, 2019",2019-10-29 10:49:00-04:00,TBPH,positive
1213671.0,"HC Wainwright & Co. Initiates Coverage On Theravance Biopharma with Buy Rating, Announces $25 Price Target",2019-10-29 07:23:00-04:00,TBPH,neutral
1213672.0,Theravance Biopharma Reports 'Positive' Results from its Phase 1 Clinical Trial of TD-8236,2019-09-09 07:12:00-04:00,TBPH,neutral
1213673.0,UK's Woodford Equity Income Fund Suspended,2019-08-20 15:22:00-04:00,TBPH,negative
1213674.0,"Theravance Biopharma Q2 EPS $(0.72) Beats $(1.24) Estimate, Sales $26.15M Beat $10.87M Estimate",2019-07-31 07:20:00-04:00,TBPH,neutral
1213675.0,Theravance Biopharma Reports New Data From Phase 2 Study Of Ampreloxetine (TD-9855) In Oral Presentation At 32nd European Neurology Congress,2019-07-22 08:06:00-04:00,TBPH,neutral
1213676.0,Theravance Biopharma Presents New Data From Phase 2 Study Of Ampreloxetine At 2019 International Association Of Parkinsonism And Related Disorders (IAPRD) World Congress,2019-06-18 09:02:00-04:00,TBPH,neutral
1213677.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs",2019-06-15 12:38:00-04:00,TBPH,neutral
1213678.0,"Theravance Biopharma and Mylan Expand YUPELRI Development and Commercialization Agreement to Include China and Adjacent Territories, Theravance to Receive a $18.5M Upfront Payment",2019-06-14 08:12:00-04:00,TBPH,positive
1213679.0,"The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix",2019-06-07 07:24:00-04:00,TBPH,positive
1213680.0,"The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering",2019-06-06 07:37:00-04:00,TBPH,neutral
1213681.0,Theravance Biopharma Names Andrew Hindman CFO,2019-06-04 08:31:00-04:00,TBPH,neutral
1213682.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,TBPH,positive
1213683.0,"The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug",2019-05-30 07:33:00-04:00,TBPH,positive
1213684.0,"The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation",2019-05-29 07:38:00-04:00,TBPH,neutral
1213685.0,"The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice",2019-05-24 07:44:00-04:00,TBPH,neutral
1213686.0,"The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study",2019-05-22 07:34:00-04:00,TBPH,neutral
1213687.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,TBPH,negative
1213688.0,Theravance Biopharma To Present Data From Phase 1b Study Of TD-1473 At Digestive Disease Week 2019,2019-05-21 07:11:00-04:00,TBPH,neutral
1213689.0,"Theravance Biopharma, Mylan Report Presentation Of Data From Pivotal Phase 3 Efficacy Studies, 52-Week Safety Study At American Thoracic Society",2019-05-20 10:18:00-04:00,TBPH,positive
1213690.0,Theravance Biopharma Announces Data From Phase 1b Study Of TD-1473 To Be Featured In Oral Presentation At Digestive Disease Week (DDW) 2019,2019-05-14 08:33:00-04:00,TBPH,neutral
1213691.0,"Theravance Biopharma Q1 EPS $(1.32) Misses $(1.19) Estimate, Sales $5.338M Miss $16.21M Estimate",2019-05-07 16:48:00-04:00,TBPH,negative
1213692.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,TBPH,positive
1213693.0,Theravance Biopharma Announces Ampreloxetine Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress,2019-03-25 08:32:00-04:00,TBPH,neutral
1213694.0,Theravance Biopharma Announces First Patient Dosed In Phase 2b/3 Study Of TD-1473 In Patients with Ulcerative Colitis,2019-03-12 08:30:00-04:00,TBPH,neutral
1213695.0,"Theravance Biopharma Q4 EPS $(0.92) Beats $(1.06) Estimate, Sales $15.737M Miss $23.43M Estimate",2019-02-26 17:16:00-05:00,TBPH,negative
1213696.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,TBPH,positive
1213697.0,Theravance Biopharma Announces First Patient Dosed In Registrational Phase 3 Study Of Ampreloxetine (TD-9855) For The Treatment Of Symptomatic Neurogenic Orthostatic Hypotension,2019-01-28 08:31:00-05:00,TBPH,neutral
1213698.0,"Theravance Biopharma Announces First Subject Dosed In Phase 1 Clinical Trial Of TD-8236, A Novel Inhaled pan-JAK Inhibitor",2018-11-27 07:55:00-05:00,TBPH,positive
1213699.0,Theravance Biopharma Reports First Patient Dosed In Phase 2 Study Of TD-1473 In Patients With Crohn's Disease,2018-11-20 08:35:00-05:00,TBPH,neutral
1213700.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-11 09:10:00-05:00,TBPH,neutral
1213701.0,"Theravance, Mylan Press Release Confirms Received FDA Approval For YUPELRI In Adults With Chronic Obstructive Pulmonary Disease",2018-11-09 15:14:00-05:00,TBPH,positive
1213702.0,"UPDATE: FDA Access Data Doc Shows Medication Guide For Theravance, Mylan's YUPELRI Was Approved By FDA",2018-11-09 13:20:00-05:00,TBPH,positive
1213703.0,"Traders Circulate FDA Access Data Doc Showing Highlights Of Prescribing Information For Theravance, Mylan's YUPELRI",2018-11-09 13:18:00-05:00,TBPH,neutral
1213704.0,"Theravance Biopharma Q3 EPS $(1.10) Beats $(1.15) Estimate, Sales $12.838M Miss $14.06M Estimate",2018-11-06 16:46:00-05:00,TBPH,negative
1213705.0,"Cumberland Pharma To Purchase VIBATIV From Theravance Biopharma For $20M Plus $5M In Added Payment In Early 2019, Tiered Royalties Of Up To 20% On Future US Net Product Sales",2018-11-06 08:33:00-05:00,TBPH,neutral
1213706.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,TBPH,positive
1213707.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,TBPH,neutral
1213708.0,Theravance Biopharma Reports Presentation Of Data From TD-1473 Phase 1b 4-Week Study In Oral Late-Breaker Presentation At United European Gastroenterology Week,2018-10-22 08:13:00-04:00,TBPH,positive
1213709.0,Theravance Biopharma Mylan Reported Positive Data From Multiple Studies Of YUPELRI At 2018 CHEST Annual Meeting,2018-10-11 08:33:00-04:00,TBPH,positive
1213710.0,Theravance Biopharma And Mylan To Present New Data From Studies Of YUPELRI At 2018 CHEST Annual Meeting,2018-10-08 08:35:00-04:00,TBPH,neutral
1213711.0,Theravance Biopharma Reports 'Positive' New Data from Multiple Studies of VIBATIV at IDWeek 2018,2018-10-08 07:30:00-04:00,TBPH,neutral
1213712.0,"Theravance Biopharma In 8-K Says On Oct. 3, CFO Renee D. Gala Notified Co. Of Resignation As On Jan. 2, 2019",2018-10-04 08:19:00-04:00,TBPH,negative
1213713.0,Theravance Biopharma To Present New Data From Multiple Studies Of VIBATIV (telavancin) At IDWeek 2018 Oct. 3-7,2018-10-01 08:14:00-04:00,TBPH,neutral
1213714.0,Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe,2018-09-24 08:32:00-04:00,TBPH,positive
1213715.0,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-16 14:22:00-04:00,TBPH,neutral
1213716.0,Theravance Biopharma shares are down 1.1% as traders circulate ClinicalTrials.gov document showing Phase Telavancin was terminated due to lack of statistical power; No safety concerns identified.,2018-09-12 10:40:00-04:00,TBPH,positive
1213717.0,Watching Thervance Biopharma Shares As Traders Circulating ClinicalTrials.gov Doc Showing Phase 3 Telavancin Trial Terminated 'due to lack of statistical power',2018-09-12 10:37:00-04:00,TBPH,neutral
1213718.0,Form 4 Filing Late Thursday Showed Theravance Biopharma EVP Bradford Shafer Sold a Total of 31.3K Shares at Avg. Prices Ranging From $27.63-$29.28,2018-08-10 08:48:00-04:00,TBPH,positive
1213719.0,UPDATE: Piper Jaffray On Thervance Says 'It Looks Like Theravance Has A New $500M+ Drug',2018-08-01 11:41:00-04:00,TBPH,positive
1213721.0,"Theravance Biopharma Q2 EPS $(0.76) Beats $(1.20) Estimate, Sales $23.48M Beat $10.67M Estimate",2018-08-01 07:17:00-04:00,TBPH,neutral
1213722.0,Theravance Biopharma Reports Top-Line Four-Week Data From Phase 2 Trial of TD-9855 For Treatment of Symptomatic Neurogenic Orthostatic Hypotension,2018-08-01 07:01:00-04:00,TBPH,neutral
1213723.0,Theravance Biopharma Announces Submission of Regulatory Application in Japan for Trelegy Ellipta,2018-05-29 16:22:00-04:00,TBPH,neutral
1213724.0,Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching,2018-05-19 16:10:00-04:00,TBPH,positive
1213725.0,Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients,2018-04-25 08:37:00-04:00,TBPH,positive
1213726.0,Theravance Biopharma Reports 'Positive' New Data from Multiple Studies of VIBATIV at 2018 ECCMID Conference,2018-04-23 07:34:00-04:00,TBPH,neutral
1213727.0,"Theravance Biopharma Reports Q4 EPS $(1.64) vs $(1.36) In Same Qtr. Last Year, Sales $4.515M",2018-02-27 17:02:00-05:00,TBPH,neutral
1213728.0,Theravance Biopharma Q4 Earnings Outlook,2018-02-27 11:41:00-05:00,TBPH,neutral
1213729.0,Theravance Biopharma Reports Submission Of IMPACT Data To EMA For Supporting Of Expanded Label For Trelegy Ellipta,2018-02-15 08:37:00-05:00,TBPH,positive
1213730.0,30 Biggest Movers From Yesterday,2018-02-08 05:04:00-05:00,TBPH,neutral
1213731.0,33 Stocks Moving In Wednesday's Mid-Day Session,2018-02-07 12:16:00-05:00,TBPH,neutral
1213732.0,Theravance Biopharma Reports Entered Global Collaboration With J&J's Janssen For TD-1473 In Inflammatory Intestinal Diseases,2018-02-07 07:38:00-05:00,TBPH,neutral
1213733.0,"Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin, FDA Assigns PDUFA Target Action Date of November 13, 2018",2018-01-29 08:31:00-05:00,TBPH,positive
1213734.0,Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta,2017-11-28 07:05:00-05:00,TBPH,positive
1213735.0,"Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta, Launch of Trelegy Ellipta in Europe Expected Before End of Year",2017-11-16 16:13:00-05:00,TBPH,neutral
1213736.0,Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin in Adults with Chronic Obstructive Pulmonary Disease,2017-11-13 09:29:00-05:00,TBPH,neutral
1213737.0,"Theravance Biopharma Reports Q3 EPS $(1.27) vs $(1.20) Est., Sales $4.275M vs $4.61M Est.",2017-11-07 16:51:00-05:00,TBPH,neutral
1213738.0,"Theravance, Mylan To Offer Added Phase 3 Data For TD-4208 At CHEST: 'Presentations Highlight 24-Hour Serial Spirometry Subgroup Findings from 2 Replicate Pivotal Phase 3 Studies; Improvements Observed in St. George's Respiratory Questionnaire...'",2017-11-01 08:32:00-04:00,TBPH,positive
1213739.0,Theravance Biopharma Says Preliminary Findings Demonstrate Clinical Response Rates with VIBATIV (telavancin) Treatment for Patients with Lower Respiratory Tract Infections,2017-10-31 08:36:00-04:00,TBPH,negative
1213740.0,Theravance Biopharma Reports 'Positive' New Data from Multiple Studies of VIBATIV,2017-10-09 08:31:00-04:00,TBPH,neutral
1213741.0,"Theravance Biopharma, GlaxoSmithKline and Innoviva Announce IMPACT Study Shows Trelegy Ellipta Met Its Primary Endpoint With Statistical Significance",2017-09-20 16:07:00-04:00,TBPH,positive
1213742.0,"Theravance Biopharma Highlights Approval of Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US, Is Entitled To Receive 85% Economic Interest In Trelegy Ellipta Royalties",2017-09-19 08:35:00-04:00,TBPH,positive
1213743.0,"Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta, Is Entitled To Receive 85% Economic Interest In Closed Triple Royalties Paid By GSK",2017-09-18 08:34:00-04:00,TBPH,positive
1213744.0,"Evercore ISI Group Initiates Coverage On Theravance Biopharma, Inc. - Ordinary Shares with Outperform Rating",2017-08-17 07:36:00-04:00,TBPH,positive
1213745.0,"Theravance Biopharma Reports Q2 Loss/Share $(1.27) vs. $(1.14) Est., Sales $3.5M vs. $4.66M Est.",2017-08-08 16:41:00-04:00,TBPH,neutral
1213746.0,Theravance Biopharma Reports Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis,2017-08-02 07:17:00-04:00,TBPH,neutral
1213747.0,"Theravance, Mylan Report Results of Phase 3 TD-4208 Study 'demonstrated that revefenacin was generally well-tolerated, and no new safety issues were identified'",2017-07-19 16:26:00-04:00,TBPH,positive
1213748.0,"Theravance Biopharma, Mylan Report Results From 12-Month Phase 3 Safety Study Of TD-4208 In Patients With COPD: Data Supports NDA Filing Expected For Q4'17",2017-07-19 16:26:00-04:00,TBPH,positive
1213749.0,"Cantor Fitzgerald Initiates Coverage On Theravance Biopharma, Inc. - Ordinary Shares with Overweight Rating, Announces $55.00 Price Target",2017-06-16 06:30:00-04:00,TBPH,negative
1213751.0,Theravance Says VIBATIV (telavancin) Demonstrates Greater in vitro Activity Compared to Competitor Antibiotics Against Range of Challenging Infection Types,2017-06-05 08:32:00-04:00,TBPH,positive
1213752.0,Theravance Reaffirms FY17 Operating Loss $205M-$195M,2017-05-09 17:35:00-04:00,TBPH,negative
1213753.0,UPDATE: Theravance Biopharma Reports Q1 Sales $3.08M vs $5.5M Est.,2017-05-09 17:35:00-04:00,TBPH,neutral
1213754.0,Theravance Biopharma Reports Q1 EPS $(1.27) vs $(1.14) Est.,2017-05-09 17:34:00-04:00,TBPH,neutral
1213755.0,Theravance Biopharma Reports Positive Clinical Response Rates for Patients in TOUR Patient Registry: VIBATIV Response Rates Treatment Range 58-75%,2017-04-24 08:54:00-04:00,TBPH,positive
1213756.0,Theravance Biopharma Announces Prelim. Data from TOUR Highlights Which Show Positive Clinical Response Rate Across Several Difficult-to-Treat Infection Types,2017-04-18 08:13:00-04:00,TBPH,positive
1213757.0,"Theravance Biopharma Reports Q4 EPS $(1.36) vs. $(1.05) Est., Sales $5.69M vs. $4.9M Est.",2017-02-27 16:13:00-05:00,TBPH,neutral
1213758.0,Theravance Biopharma Reports Clinical Data on TD-1473: Further Data from Phase 1 Trial Reaffirms Favorable Tolerability of Single and Multiple Oral Doses of TD-1473 and Minimal Systemic Exposure in Healthy Subjects,2017-02-17 08:31:00-05:00,TBPH,positive
1213759.0,How To Invest Like Seth Klarman,2017-02-09 08:43:00-05:00,TBPH,positive
1213760.0,Theravance Biopharma Reports New Data from Ongoing TOUR Observational Patient Registry: Show VIBATIV Generates Positive Clinical Response Rate of ~65% for Patients with Bacteremia or Infective Endocarditis,2017-01-23 08:31:00-05:00,TBPH,positive
1213761.0,Theravance Biopharma Says Royalties from 'Closed Triple' Expected as Early as 2018,2017-01-09 06:15:00-05:00,TBPH,neutral
1213762.0,Theravance Says is Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Agreement with Innoviva,2016-12-19 17:47:00-05:00,TBPH,positive
1213763.0,"Theravance Shares Sell Off as $31 Support Level Breaks, Down ~$0.90 Over Last Min, Down ~5% for Session",2016-12-14 11:59:00-05:00,TBPH,positive
1213764.0,Theravance Biopharma Receives FDA Fast Track Designation For Velusetrag,2016-12-06 08:35:00-05:00,TBPH,neutral
1213765.0,"Theravance Biopharma Highlights Filing of EU Regulatory Submission for the Closed Triple in COPD by GlaxoSmithKline and Innoviva, Will Receive 85% Economic Interest In Closed Triple Royalties Paid By GSK As Part Of Agreement",2016-12-05 08:31:00-05:00,TBPH,positive
1213766.0,Theravance Biopharma Highlights Filing of U.S. New Drug Application for the Closed Triple in COPD by GlaxoSmithKline and Innoviva,2016-11-21 16:38:00-05:00,TBPH,neutral
1213767.0,Theravance Biopharma Spikes to High of $33.43 on Volume,2016-11-11 11:21:00-05:00,TBPH,neutral
1213768.0,"Theravance Biopharma Reports Q3 Loss/Share $0.73 vs Est Loss/Share $0.92, Revenue $19.1M vs $12.62M Est",2016-11-08 16:07:00-05:00,TBPH,neutral
1213769.0,Benzinga's Top Initiations,2016-11-03 09:21:00-04:00,TBPH,positive
1213770.0,"The Market In 5 Minutes: Facebook Beats, First Solar Falls And A 108-Year Drought Ends",2016-11-03 08:58:00-04:00,TBPH,neutral
1213771.0,"PiperJaffray Initiates Coverage On Theravance Biopharma, Inc. - Ordinary Shares at Overweight, Announces $42.00",2016-11-03 06:37:00-04:00,TBPH,negative
1213772.0,Theravance Says 'TOUR Results Highlight Clinical Response Rates for VIBATIV® (telavancin) in a Range of Difficult-to-Treat Infections',2016-10-31 08:37:00-04:00,TBPH,positive
1213773.0,Theravance Biopharma Prices 3.85M Share Offering @$26.00/Share,2016-10-28 04:04:00-04:00,TBPH,positive
1213774.0,Theravance Biopharma Announces Proposed Public Offerings of $100 Million of Ordinary Shares,2016-10-26 16:21:00-04:00,TBPH,positive
1213775.0,Theravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714,2016-10-25 08:33:00-04:00,TBPH,positive
1213776.0,Theravance Biopharma and Mylan Say Revefenacin Phase 3 Study Met Primary Endpoints,2016-10-20 06:57:00-04:00,TBPH,neutral
1213777.0,Theravance Biopharma's Valuation Has Gotten A Little Carried Away,2016-10-12 13:21:00-04:00,TBPH,neutral
1213778.0,12 Biggest Mid-Day Losers For Wednesday,2016-10-12 12:24:00-04:00,TBPH,negative
1213779.0,Mid-Morning Market Update: Markets Mostly Flat; Stanley Black & Decker To Buy Newell Tool Unit For $1.95B,2016-10-12 10:01:00-04:00,TBPH,neutral
1213780.0,"The Market In 5 Minutes: Fed Focus, British Pound, More Earnings",2016-10-12 09:01:00-04:00,TBPH,neutral
1213781.0,Benzinga's Top Downgrades,2016-10-12 08:59:00-04:00,TBPH,positive
1213782.0,"Baird Downgrades Theravance Biopharma, Inc. to Underperform",2016-10-12 04:43:00-04:00,TBPH,neutral
1213783.0,Theravance Biopharma Reports Initial Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis,2016-10-04 08:06:00-04:00,TBPH,negative
1213784.0,"UPDATE: Theravance Says GSK's Regulatory Submissions On Track for Closed Triple in US, Europe by End of '16",2016-09-07 17:06:00-04:00,TBPH,neutral
1213785.0,UPDATE: Theravance Biopharma Says Will Be Entitled to Receive 85% Economic Interest in Closed Triple Royalties Paid by GSK as Part of Deal with Innoviva,2016-09-07 17:05:00-04:00,TBPH,positive
1213786.0,Theravance Bipharma Announces Clinically Meaningful Benefits For The Closed Triple,2016-09-07 17:05:00-04:00,TBPH,positive
1213787.0,Benzinga's Top Initiations,2016-08-29 08:59:00-04:00,TBPH,positive
1213788.0,"Evercore ISI Group Initiates Coverage on Theravance Biopharma at Buy, Announces $41.00 PT",2016-08-29 07:56:00-04:00,TBPH,neutral
1213789.0,"Theravance Biopharma Reports Q2 EPS $(1.06) vs. Est. $(1.05), Rev. $5.47M vs. Est. $12.7M",2016-08-08 16:23:00-04:00,TBPH,neutral
1213790.0,The Market In 5 Minutes: Downtrend Continues,2016-08-03 08:59:00-04:00,TBPH,neutral
1213791.0,Bank of America Downgrades Theravance Biopharma to Underperform,2016-08-03 06:58:00-04:00,TBPH,neutral
1213792.0,"Theravance Biopharma Highlights Positive Top-Line Results from Pivotal Phase 3 FULFIL Study of Closed Triple Announced by GlaxoSmithKline, Innoviva",2016-06-20 21:15:00-04:00,TBPH,positive
1213793.0,Theravance Biopharma Reports New Positive Data From Several VIBATIV Studies,2016-06-20 08:07:00-04:00,TBPH,positive
1213794.0,Guggenheim Securities Initiates Coverage on Theravance Biopharma at Buy,2016-06-20 06:22:00-04:00,TBPH,positive
1213795.0,Theravance Announces Takeda Has Licensed Global Rights to Co.'s TD-8954,2016-06-08 08:06:00-04:00,TBPH,neutral
1213796.0,Theravance Biopharma Reports Phase 3 ATTAIN Trials Shows No Statistically Significant Differences In Nephrotoxicity & Moralivty For Telavancin vs. Vancomycin,2016-05-16 08:06:00-04:00,TBPH,negative
1213797.0,"Theravance Biopharma Reports Q1 EPS $(1.10) Vs Est $(0.96), Sales $18.410 Vs Est $18.69M",2016-05-09 16:57:00-04:00,TBPH,neutral
1213798.0,Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV,2016-05-09 08:12:00-04:00,TBPH,positive
1213799.0,Bank of America Downgrades Theravance Biopharma to Neutral,2016-05-05 07:27:00-04:00,TBPH,neutral
1213800.0,Theravance Biopharma Announces Proposed Public Offering 4.25M Ordinary Shares,2016-04-27 17:18:00-04:00,TBPH,positive
1213801.0,Theravance Biopharma Shows Greater In Vitro Potrency vs. Other Antibiotic Treatments For Difficult-to-Treat-Pathogens,2016-04-11 08:07:00-04:00,TBPH,positive
1213802.0,Theravance Biopharma To Show  New Data Demonstrating Strong In Vitro Activity For VIBATIV Against Difficult-to-Treat Infections At 2016 ECCMID,2016-04-04 08:07:00-04:00,TBPH,positive
1213803.0,Theravance Biopharma Holder GlaxoSmithKline Reports 24.3% Stake As Of March 14,2016-03-24 16:20:00-04:00,TBPH,neutral
1213804.0,"Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, Showed To Be Significant Pan-JAK Inhibitor",2016-03-18 07:33:00-04:00,TBPH,positive
1213805.0,Theravance Biopharma And Glaxo Group Enter Agreement Where Theravance To Sell 1.3M Shares At $17.70/Share For $23M,2016-03-14 08:09:00-04:00,TBPH,positive
1213806.0,Theravance Biopharma Reports Q4 Rev. $3.893M,2016-03-09 16:18:00-05:00,TBPH,neutral
1213807.0,Theravance Biopharma Reports Q4 EPS $(1.23) vs. Est. $(1.62),2016-03-09 16:18:00-05:00,TBPH,neutral
1213808.0,"Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin, Study Shows Maximal & Sustained Target Enhancement",2016-03-09 07:30:00-05:00,TBPH,positive
1213809.0,Theravance Biopharma Announces Launch Of New Drug In Canada; Investors Shrugging Off News,2016-01-26 12:19:00-05:00,TBPH,neutral
1213810.0,Theravance Biopharma Reports Launch Of Vibativ In Canada,2016-01-26 08:05:00-05:00,TBPH,neutral
1213811.0,Theravance Biopharma Reports Initial Patient Dosed In Phase 1 Trial Of TD-1473,2015-12-10 08:06:00-05:00,TBPH,neutral
1213812.0,"Theravance Biopharma Doses Initial Patient In Phase 1 Clinical Of TD-0714, Company's neprilysin Inhibitor Program",2015-12-08 08:06:00-05:00,TBPH,negative
1213813.0,"Theravance Biopharma Reports Q3 EPS $(1.40) vs. Est. $(1.44), Rev. $10.7M vs. Est. $4.24M",2015-11-09 16:47:00-05:00,TBPH,neutral
1213814.0,"Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor",2015-11-02 08:05:00-05:00,TBPH,negative
1213815.0,"Theravance Biopharma and Trek Therapeutics Report Initiation of Phase 2a Trial of TD-6450, an NS5A Inhibitor to Treat Hepatitis C",2015-10-27 08:05:00-04:00,TBPH,positive
1213816.0,Woodford Investment Management Acquires 3.859M Shares Of Theravance Biopharma For $14.25/Share,2015-10-26 08:10:00-04:00,TBPH,positive
1213817.0,"Data From New Retrospective Studies of VIBATIV(R) (Telavancin) Demonstrate Positive Clinical Outcomes for Patients With Difficult-to-Treat, Gram-Positive Infections, Including MRSA",2015-10-12 08:08:00-04:00,TBPH,positive
1213818.0,"Theravance Biopharma to Show New Retrospective Clinical Data on VIBATIV Showing Positive Outcomes for Patients With Difficult-to-Treat Infections, Including MRSA, at IDWeek 2015",2015-10-05 08:05:00-04:00,TBPH,positive
1213819.0,"Data From New Studies Confirm In Vitro Potency of VIBATIV Against Gram-Positive Bacteria, Including MRSA",2015-09-21 08:07:00-04:00,TBPH,neutral
1213820.0,"Theravance Biopharma, Mylan Report Initiation of Phase 3 Program for Revefenacin for the Treatment of COPD",2015-09-14 08:06:00-04:00,TBPH,neutral
1213821.0,Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination of Axelopran  and Oxycodone at PAINWeek 2015,2015-09-10 08:05:00-04:00,TBPH,positive
1213822.0,Theravance Biopharma Report FDA Acceptance of sNDA to Expand VIBATIV Labeling,2015-09-10 07:55:00-04:00,TBPH,positive
1213823.0,"Theravance Biopharma to Present New Data Highlighting in vitro Potency of VIBATIV(R) (telavancin) Against Gram-Positive Bacteria, Including MRSA, at 2015 ICAAC",2015-09-08 08:16:00-04:00,TBPH,neutral
1213824.0,GlaxoSmithKline Holder Theravance Reports 24.5% Stake As Of Dec 31,2015-09-02 12:48:00-04:00,TBPH,neutral
1213825.0,"Theravance Biopharma Reports Q2 Loss $1.42 vs Est Loss $1.51, Sales #7.13M Vs Est $4.25M",2015-08-10 16:37:00-04:00,TBPH,negative
1213826.0,"Theravance Biopharma Reports Health Canada Approval for VIBATIV(R) (telavancin) for Treatment of HAP/VAP Caused by Gram-Positive Bacteria, Including MRSA",2015-07-23 08:06:00-04:00,TBPH,positive
1213827.0,Theravance Biopharma Reports Marketing Authorization for VIBATIV(R) in Russia for Treatment of Multiple Infections Caused by Gram-Positive Bacteria,2015-06-30 08:06:00-04:00,TBPH,neutral
1213828.0,"SciClone Pharmaceuticals, Theravance Biopharma Enter Development & Commercialization Agreement for VIBATIV (Telavancin) in China",2015-05-27 08:06:00-04:00,TBPH,positive
1213829.0,Theravance Biopharma Presents Additional Positive Phase 2b Study Data on TD-4208,2015-05-20 08:06:00-04:00,TBPH,positive
1213830.0,Theravance Biopharma Presents Positive Phase 2 Study Data on Velusetragfor Treatment of Gastroparesis,2015-05-18 08:06:00-04:00,TBPH,positive
1213831.0,"Theravance Biopharma Presents New Data Highlighting in vitro Potency of VIBATIV(R) (telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, at 2015 ECCMID Conference",2015-04-16 08:05:00-04:00,TBPH,neutral
1213832.0,Theravance Reports Q4 Loss of $2.02/Share vs Loss of $1.70/Share Est.,2015-03-10 16:28:00-04:00,TBPH,negative
1213833.0,Theravance Biopharma Reports Enrollment of First Patient in Phase 3 Registrational Study of Telavancin in Staphylococcus Aureus Bacteremia,2015-02-24 08:06:00-05:00,TBPH,neutral
1213834.0,Theravance Biopharma Initiates Patient Registry Study for VIBATIV,2015-02-10 08:12:00-05:00,TBPH,neutral
1213835.0,Benzinga's Volume Movers,2015-02-02 10:29:00-05:00,TBPH,neutral
1213836.0,"Theravance, Mylan Partner to Develop and Commercialize Novel LAMA Compound, TD-4208, for COPD",2015-02-02 07:12:00-05:00,TBPH,positive
1213837.0,19 Lesser-Known Biotech Stocks With Robust Drug Pipelines,2014-12-31 08:59:00-05:00,TBPH,positive
1213838.0,Theravance Biopharma Reports Q3 EPS of $(1.72) vs $(1.85) Est; Revenue of $6.30M vs $1.49M Est,2014-11-06 16:17:00-05:00,TBPH,neutral
1213839.0,Morning Market Movers ,2014-11-04 09:49:00-05:00,TBPH,neutral
1213840.0,Benzinga's Top #PreMarket Gainers,2014-11-04 08:10:00-05:00,TBPH,positive
1213841.0,Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study of TD-6450 ,2014-11-03 16:24:00-05:00,TBPH,positive
1213842.0,Theravance Biopharma Provides VIBATIV (telavancin) Product Update ,2014-09-09 08:06:00-04:00,TBPH,neutral
1213843.0,"Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Dose-Ranging Study of its Investigational LAMA, TD-4208, for the Treatment of COPD ",2014-09-08 16:05:00-04:00,TBPH,positive
1213844.0,Benzinga's Top Downgrades,2014-08-14 09:23:00-04:00,TBPH,positive
1213845.0,Baird Downgrades Theravance Biopharma To Underperform,2014-08-14 08:25:00-04:00,TBPH,neutral
1213846.0,"Baird Downgrades Theravance Biopharma to Underperform, Maintains $21.00 PT",2014-08-14 06:41:00-04:00,TBPH,neutral
1213847.0,Theravance Biopharma Reports Q2 EPS of $(1.83); Revenue of $2.97M,2014-08-13 16:39:00-04:00,TBPH,neutral
1213848.0,"Bank of America Initiates Coverage on Theravance Biopharma at Buy, Announces $34.00 PT",2014-06-06 07:52:00-04:00,TBPH,neutral
